JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Incyte Corp

Fechado

SetorSaúde

70.33 -0.38

Visão Geral

Variação de preço das ações

24h

Atual

Mín

70.03

Máximo

70.63

Indicadores-chave

By Trading Economics

Rendimento

-43M

158M

Vendas

-126M

1.1B

P/E

Médio do Setor

336.9

38.156

EPS

1.16

Margem de lucro

15.025

Funcionários

2,617

EBITDA

-80M

257M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+13.39% upside

Dividendos

By Dow Jones

Próximos Ganhos

29 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-3B

13B

Abertura anterior

70.71

Fecho anterior

70.33

Sentimento de Notícias

By Acuity

83%

17%

353 / 375 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Incyte Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

25 de jul. de 2025, 17:53 UTC

Grandes Movimentos do Mercado

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25 de jul. de 2025, 15:58 UTC

Ganhos
Grandes Movimentos do Mercado

Aon Shares Rise After 2Q Earnings Beat

25 de jul. de 2025, 15:08 UTC

Grandes Movimentos do Mercado

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25 de jul. de 2025, 21:40 UTC

Conversa de Mercado

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25 de jul. de 2025, 21:23 UTC

Conversa de Mercado

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25 de jul. de 2025, 20:40 UTC

Ganhos

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 de jul. de 2025, 20:10 UTC

Ganhos

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 de jul. de 2025, 19:56 UTC

Ganhos

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25 de jul. de 2025, 19:14 UTC

Conversa de Mercado

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25 de jul. de 2025, 19:10 UTC

Conversa de Mercado

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25 de jul. de 2025, 19:01 UTC

Ganhos

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 de jul. de 2025, 18:45 UTC

Conversa de Mercado

Gold Ends Down Week on Lower Note -- Market Talk

25 de jul. de 2025, 18:35 UTC

Aquisições, Fusões, Aquisições de Empresas

Sale Could Fetch Around $1B, Sources Say -- WSJ

25 de jul. de 2025, 18:35 UTC

Aquisições, Fusões, Aquisições de Empresas

LVMH in Talks to Sell Marc Jacobs -- WSJ

25 de jul. de 2025, 18:35 UTC

Aquisições, Fusões, Aquisições de Empresas

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25 de jul. de 2025, 18:35 UTC

Aquisições, Fusões, Aquisições de Empresas

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25 de jul. de 2025, 17:38 UTC

Grandes Movimentos do Mercado

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25 de jul. de 2025, 17:26 UTC

Conversa de Mercado

U.S. Oil Rig Count Extends Decline -- Market Talk

25 de jul. de 2025, 17:13 UTC

Ganhos

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 de jul. de 2025, 16:46 UTC

Ganhos

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25 de jul. de 2025, 16:45 UTC

Ganhos

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25 de jul. de 2025, 16:27 UTC

Ganhos

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

25 de jul. de 2025, 16:02 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25 de jul. de 2025, 15:34 UTC

Ganhos

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25 de jul. de 2025, 15:06 UTC

Conversa de Mercado

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25 de jul. de 2025, 15:05 UTC

Ganhos

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25 de jul. de 2025, 14:45 UTC

Conversa de Mercado

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25 de jul. de 2025, 14:44 UTC

Conversa de Mercado

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25 de jul. de 2025, 14:36 UTC

Conversa de Mercado
Ganhos

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Comparação entre Pares

Variação de preço

Incyte Corp Previsão

Preço-alvo

By TipRanks

13.39% parte superior

Previsão para 12 meses

Média 79.6 USD  13.39%

Máximo 107 USD

Mínimo 52 USD

Com base em 17 analistas de Wall Street que oferecem metas de preço de 12 meses para Incyte Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

17 ratings

7

Comprar

9

Manter

1

Vender

Pontuação Técnica

By Trading Central

59.52 / 62.66Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

353 / 375 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation